Jeanette Weidner was named Vice President, Finance of Gain Therapeutics, Inc. As of November 6, 2026, Gain Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 28, 2026 to October 28, 2026, naming 2 appointments (Form 8-K, October 28, 2026).
Gain Therapeutics, Inc. named a new Chief Financial Officer on Sep 28. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Gain Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Gain Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-28 to 2026-10-28. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Gain Therapeutics, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-28 | In | Vice President, Finance | 8-K, 2026-10-28 | ||
| 2026-09-28 | In | Chief Financial Officer | 2026-10-01 | 8-K, 2026-09-28 |
Selling to them or working with them? See who runs Gain Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Watch Gain Therapeutics, Inc.
Get an email when Gain Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Gain Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Gain Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Gain Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Gain Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Vice President, Finance: Jeanette Weidner, appointed (filed 2026-10-28).
- Chief Financial Officer: Gene Mack, appointed, effective 2026-10-01 (filed 2026-09-28).
New leaders reset buying decisions — get the Full Report on Gain Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Vice President, Finance at Gain Therapeutics, Inc., with the record behind each one.
Find candidates like Finance at Gain Therapeutics, Inc.Every change, in the filing's words
Appointed: Jeanette Weidner, Vice President, Finance
On October 22, 2026, Gain Therapeutics, Inc. (the "Company") appointed Jeanette Weidner as its Vice President, Finance, with an effective date of October 28, 2026 (the "Effective Date").
- In this role, Ms. Weidner will also serve as the Company's principal financial officer and principal accounting officer.
- Ms. Weidner, 44, has 18 years of experience in accounting and finance including more than a decade in the life sciences industry spanning medical devices, regenerative medicine, and biopharmaceuticals.
- Prior to joining the Company, Ms. Weidner served as a financial consultant for Senseonics Holdings Inc. (Nasdaq: SENS), a medical technology company focused on continuous glucose monitoring products, from March 2025 to October 2026.
- At Senseonics, Ms. Weidner focused on financial reporting and operational accounting.
- Prior to Senseonics, Ms. Weidner was Vice President, Finance, for OncoC4, Inc., a private late clinical-stage biopharmaceutical company engaged in the discovery and development of novel biologics for the potential treatment of cancer, from March 2021 to January 2025.
- At OncoC4, Ms. Weidner lead and developed the accounting and finance function from the inception of the organization through Phase III clinical trials.
- Before her time at OncoC4, Ms. Weidner held roles of Controller and Assistant Controller at various life sciences companies.
- Ms. Weidner received her undergraduate degree from Salisbury University and subsequently studied accounting through the University of Maryland Global Campus.
Appointed: Gene Mack, Chief Financial Officer, effective 2026-10-01
On September 24, 2026, the Company's board of directors appointed Gene Mack, the Company's current President and Chief Executive Officer, to serve as the Company's interim Chief Financial Officer, effective as of October 1, 2026.
- Resignation of Principal Financial Officer On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer of Gain Therapeutics, Inc. (the "Company"), notified the Company of his intention to resign from his positions with the Company, with such resignation to be effective September 30, 2026, in order to pursue other opportunities.
- In connection with this appointment, Mr. Mack will continue in his roles as President and Chief Executive Officer and will assume the duties of the Company's principal financial officer and principal accounting officer until his successor is appointed or until his earlier resignation or removal, and until such time as a permanent replacement is named.
- The Company is engaged in an ongoing search for a permanent replacement to serve as its principal financial officer and principal accounting officer.
- The compensatory and other material terms of Mr. Mack's employment with the Company will remain unchanged in connection with the foregoing.
Tools for this story
Each opens in a new tab, filled in for Gain Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.